Minerva Neurosciences Inc. | Mutual Funds
Mutual Funds that own Minerva Neurosciences Inc.
Federated Kaufmann Fund
6,075,000
15.67%
-250,000
0.93%
06/29/2018
Fidelity Select Biotechnology Portfolio
3,088,389
7.97%
-62,225
0.35%
07/31/2018
Fidelity Advisor Biotechnology Fund
1,357,162
3.5%
-60,618
0.49%
07/31/2018
Federated Kaufmann Small Cap Fund
1,297,300
3.35%
242,300
0.84%
06/29/2018
Highland Long/Short Healthcare Fund
941,578
2.43%
18,430
7.55%
12/31/2017
T Rowe Price Health Sciences Fund
900,227
2.31%
-15,309
0.07%
06/30/2018
Vanguard Total Stock Market Index Fund
858,347
2.21%
0
0%
07/31/2018
FTIF SICAV - Franklin Biotechnology Discovery Fund
808,200
2.08%
0
0.36%
06/30/2018
Highland Premier Growth Equity Fund
740,423
1.91%
202,500
4.29%
12/31/2017
iShares Russell 2000 ETF
640,673
1.65%
-342
0.01%
09/06/2018
| Address |
1601 Trapelo Road
Waltham Massachusetts 02451
United States
|
|
Employees
|
- |
| Website |
http://www.minervaneurosciences.com |
| Updated |
07/08/2019 |
| Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. Its product portfolio includes MIN-101, MIN-117, MIN-202 and MIN-301. The company was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Cambridge, MA. |
